Insilico Medicine to present at the 2019 ACCP Annual Meeting

Monday, August 12, 2019 - Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the American College of Clinical Pharmacology® (ACCP) Annual Meeting on September 15, in Chicago.

This year's meeting is focused on "Reflecting on Our History & Shaping the Future of Clinical Pharmacology". Consistent with ACCP's commitment to excellence in science and education, the 2019 Annual Meeting Program Committee is working diligently to provide a diverse and exceptional educational program that meets the needs of healthcare professionals and scientists with an interest in one or more of the myriad of applications of clinical pharmacology ranging from research and drug development to patient care. Speakers spanning the breadth of academia, industry, regulatory agencies, consulting companies and clinical specialties will present educational and scientific programs organized into topic tracks that allow attendees to uniquely tailor content selection to their individual interests. In 2019, the American College of Clinical Pharmacology® (ACCP) will be celebrating its 50th Anniversary.

"I am deeply honored to be invited as a keynote speaker to the 50th annual American College of Clinical Pharmacology in Chicago this year that will bring together an amazing lineup of colleagues from big pharma and biotech. We will be announcing one of our big breakthroughs in generative chemistry so please consider attending this event," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.

Artificial intelligence has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments. At Insilico, artificial intelligence has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.

###

For further information, images or interviews, please contact:

Contact: Klug Gehilfe ai@pharma.ai

Website: http://insilico.com/

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

About Insilico Medicine

Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8.

Website: http://insilico.com/



This story has been published on: 2019-08-12. To contact the author, please use the contact details within the article.



Comments

We use a third-party service called Disqus to enable our visitors to post comments to our website. Due to the amount of comments, we do not moderate or review posted comments on our website.

Discover 7thSpace